Non-alcoholic fatty liver disease and flavonoids: Current perspectives

被引:21
|
作者
Shin, Jung Hee [1 ]
Jung, Ji Hye [2 ]
机构
[1] Joongbu Univ, Dept Food & Nutr, 201 Daehak Ro, Geumsan Gun, Chungcheongnam, South Korea
[2] Inje Univ, Inst Clin Nutr, Mareunnae Ro 9, Seoul, South Korea
关键词
KAPPA-B ACTIVATION; OXIDATIVE STRESS; CHOLESTEROL ACCUMULATION; HEPATIC CHOLESTEROL; INSULIN SENSITIVITY; ANTIOXIDANT STATUS; LIPID-METABOLISM; SOY ISOFLAVONES; GENE-EXPRESSION; OBESE;
D O I
10.1016/j.clinre.2016.07.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat in the liver despite a low level of alcohol intake, with signs of hepatomegaly. Although in the past, NAFLD was predominantly viewed as an aspect of metabolic syndrome, it is now considered that it should be classified as an independent condition similar to obesity, diabetes, and hypertension. Therefore, new treatment strategies, not based on correcting insulin resistance, are needed for NAFLD. This work analyzes methods of prevention, therapeutic approaches, and mechanisms involved in NAFLD, focusing on the use of flavonoids (epigallocatechin-3-gallate, resveratrol, anthocyanins, and isoflavones) with high antioxidant capacity. In addition, the mechanisms of cholesterol accumulation in the liver are identified as potential avenues for entirely new approaches to NAFLD treatment, contrasting the well-known relation between neutral fat and NAFLD. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:17 / 24
页数:8
相关论文
共 50 条
  • [21] Current therapeutic strategies in non-alcoholic fatty liver disease
    Dowman, J. K.
    Armstrong, M. J.
    Tomlinson, J. W.
    Newsome, P. N.
    [J]. DIABETES OBESITY & METABOLISM, 2011, 13 (08): : 692 - 702
  • [22] Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
    Samarth Siddharth Patel
    Mohammad Shadab Siddiqui
    [J]. Drugs, 2019, 79 : 75 - 84
  • [23] Non-alcoholic fatty liver disease: Current therapeutic options
    Majumdar, Avik
    Verbeek, Jef
    Tsochatzis, Emmanuel A.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2021, 61 : 98 - 105
  • [24] Non-alcoholic fatty liver disease
    Angulo, P
    Lindor, KD
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
  • [25] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    [J]. PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [26] Non-alcoholic fatty liver disease
    Neuschwander-Tetri, Brent A.
    [J]. BMC MEDICINE, 2017, 15
  • [27] Non-alcoholic fatty liver disease
    Carreras, MP
    Tortajada, GC
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (05) : 377 - 377
  • [28] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    [J]. CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
  • [29] Non-alcoholic fatty liver disease
    Smith, Briohny W.
    Adams, Leon A.
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (03) : 97 - 113
  • [30] Non-alcoholic fatty liver disease
    Powell, Elizabeth E.
    Wong, Vincent Wai-Sun
    Rinella, Mary
    [J]. LANCET, 2021, 397 (10290): : 2212 - 2224